Compare FSBW & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSBW | ACRS |
|---|---|---|
| Founded | 1936 | 2012 |
| Country | United States | United States |
| Employees | 537 | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.4M | 311.0M |
| IPO Year | 2011 | 2015 |
| Metric | FSBW | ACRS |
|---|---|---|
| Price | $40.14 | $4.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $46.00 | $10.20 |
| AVG Volume (30 Days) | 13.0K | ★ 1.4M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ 4.29 | N/A |
| Revenue | ★ $4,612,000.00 | $1,683,000.00 |
| Revenue This Year | $14.94 | N/A |
| Revenue Next Year | $10.47 | $4.24 |
| P/E Ratio | $9.46 | ★ N/A |
| Revenue Growth | ★ 44.80 | N/A |
| 52 Week Low | $36.72 | $1.20 |
| 52 Week High | $44.22 | $4.89 |
| Indicator | FSBW | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 61.28 |
| Support Level | $39.28 | $3.16 |
| Resistance Level | $40.97 | $4.56 |
| Average True Range (ATR) | 0.80 | 0.23 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 22.60 | 82.93 |
FS Bancorp Inc is the holding company of First Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.